ECA Marcellus Trust I (ECTM)
| Market Cap | 11.08M +18.4% |
| Revenue (ttm) | 4.28M +51.4% |
| Net Income | 2.92M +117.0% |
| EPS | 0.17 +117.0% |
| Shares Out | 17.61M |
| PE Ratio | 3.80 |
| Forward PE | n/a |
| Dividend | 0.13 (20.34%) |
| Ex-Dividend Date | May 28, 2026 |
| Volume | 4,188 |
| Open | 0.6200 |
| Previous Close | 0.6300 |
| Day's Range | 0.5803 - 0.6293 |
| 52-Week Range | 0.4500 - 0.7600 |
| Beta | 0.27 |
| Analysts | Hold |
| Price Target | 7.00 (+1,032.14%) |
| Earnings Date | Aug 12, 2026 |
About ECA Marcellus Trust I
ECA Marcellus Trust I owns royalty interests in producing wells and horizontal natural gas development wells for Energy Corporation of America. It owns royalty interests in 14 producing wells and 40 development wells located in Greene County, Pennsylvania. The company was incorporated in 2010 and is based in Houston, Texas. [Read more]
Financial Performance
In 2025, ECA Marcellus Trust I's revenue was $3.76 million, an increase of 73.05% compared to the previous year's $2.18 million. Earnings were $2.24 million, an increase of 182.57%.
Financial StatementsNews
ECA Marcellus Trust I Announces Quarterly Distribution
HOUSTON--(BUSINESS WIRE)--ECA MARCELLUS TRUST I (OTCID Basic Market: ECTM) announced today that the Trust's distribution for the quarter ended March 31, 2026, will be $0.090 per unit, which is expecte...
Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)
CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., an innovator in sustained drug delivery for chronic retinal diseases, today announced that the U.S. Food and Drug Administration (FD...
ECA Marcellus Trust I Announces There Will Be No Quarterly Distribution
HOUSTON--(BUSINESS WIRE)--ECA MARCELLUS TRUST I (OTC Pink: ECTM) announced today that there will be no distribution paid for the quarter ended June 30, 2024, for holders of record as of the close of b...
Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel)
CUMBERLAND, R.I.--(BUSINESS WIRE)-- #mactel--Neurotech Pharmaceuticals, Inc., an innovator in sustained drug delivery for chronic retinal diseases, announces that the U.S. Food and Drug Administration...
Kontron introduces the XMC-ETH6
TOULON, France--(BUSINESS WIRE)--Kontron, a leading global provider of IoT/Embedded Computer Technology (ECT), announces the release of the XMC-ETH6, a high-performance Gigabit Ethernet XMC designed t...
ECA Marcellus Trust I Provides Update on NYSE Delisting
HOUSTON--(BUSINESS WIRE)--ECA MARCELLUS TRUST I (NYSE: ECT) today announced that it has received notification from the New York Stock Exchange (“NYSE”) of its determination to suspend trading of the T...